BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:InxMed readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies InxMed's drugs run\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06014528-2138@assetmemo.bio
DTSTAMP:20261121T004526Z
DTSTART;VALUE=DATE:20270324
DTEND;VALUE=DATE:20270325
SUMMARY:Ifebemtinib: Phase 2 readout est. (NCT06014528)
DESCRIPTION:Ifebemtinib\, phase 2.\nStudy: IN10018 in Combination With Pegy
 lated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for 
 the Treatment of Platinum-resistant Recurrent Ovarian Cancer\nEstimated pr
 imary completion: 24 March 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ifebemtinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06014528
URL:https://assetmemo.bio/drug/ifebemtinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06166836-2138@assetmemo.bio
DTSTAMP:20261121T004526Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ifebemtinib: Phase 1/2 readout est. (NCT06166836)
DESCRIPTION:Ifebemtinib\, phase 1/2.\nStudy: a Study to Evaluate the Safety
  and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tu
 mors\nEstimated primary completion: 31 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ifebemtinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06166836
URL:https://assetmemo.bio/drug/ifebemtinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174908-2138@assetmemo.bio
DTSTAMP:20261121T004526Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Ifebemtinib: Phase 3 readout est. (NCT07174908)
DESCRIPTION:Ifebemtinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy
  for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mut
 ation\nEstimated primary completion: September 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ifebemtinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07174908
URL:https://assetmemo.bio/drug/ifebemtinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441174-2138@assetmemo.bio
DTSTAMP:20261121T004526Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Ifebemtinib: Phase 1/2 readout est. (NCT07441174)
DESCRIPTION:Ifebemtinib\, phase 1/2.\nStudy: IN10018 in Combination With RN
 K08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or
  Metastatic Solid Tumors\nEstimated primary completion: 28 February 2031. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ifebemtinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07441174
URL:https://assetmemo.bio/drug/ifebemtinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
